Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $495.29, marking a +1.42% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.49%.

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.45% to $495.42 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to ...

BTIG analyst Mark Massaro lowered the firm’s price target on MaxCyte (MXCT) to $6 from $8 and keeps a Buy rating on the shares after its Q4 ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...